Trials / Completed
CompletedNCT05767398
Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants
A Single-dose, Open-label, Randomized, Replicate Crossover Study in Healthy Adult Subjects to Assess the Bioequivalence of a Zanubrutinib Tablet Compared to Zanubrutinib Capsules
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Study to determine the bioequivalence of a zanubrutinib tablet compared to capsules in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanubrutinib | Administered as a tablet or capsule |
Timeline
- Start date
- 2023-03-07
- Primary completion
- 2023-04-28
- Completion
- 2023-04-28
- First posted
- 2023-03-14
- Last updated
- 2024-10-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05767398. Inclusion in this directory is not an endorsement.